Liquid biopsy company Angle said the University of Crete had published peer-reviewed results of new work demonstrating the potential to use the company's Parsortix liquid biopsy system to assess whether lung cancer patients would respond to immunotherapy drugs. The Univerty of Crete's laboratory of translational oncology, part of the school of medicine, released the results of study, which combined, for the first time, an assessment of PD-L1 (programmed Death-Ligand 1) with a second immune checkpoint, IDO (Indolamine-2,3-dioxygenase), on a patient's circulating tumor cells (CTCs),' the company said. The study demonstrated that the detection of IDO + CTCs, and particularly of the IDO+/PD-L1- CTC subpopulation harvested using Parsortix, was 'significantly associated with reduced progression-free survival and overall survival in NSCLC patients treated with anti-PD-1 agents,' Angle said. 'While a variety of CTC systems and approaches were evaluated in matched samples in this study, only CTC detection using ANGLE's Parsortix system was significantly associated with disease progression,' it added. At 8:26am: (LON:AGL) Angle PLC share price was +1.1p at 53.5p
Sign up to our
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
UK 350 Risers and Fallers
Tweets not available.